Title :

Advanced chordoma treated by first-line molecular targeted therapies: outcomes and prognostic factors. A retrospective study of the french sarcoma group (gsf/geto) and the association des neuro-oncologues d'expression franc, aise (anocef)

Author(s) :

Lebellec, Loic [Auteur]
Chauffert, Bruno [Auteur]
Blay, Jean-Yves [Auteur]
Le Cesne, Axel [Auteur]
Chevreau, Christine [Auteur]
Bompas, Emmanuelle [Auteur]
Bertucci, François [Auteur]
Cupissol, Didier [Auteur]
Fabbro, Michel [Auteur]
Saada-Bouzid, Esma [Auteur]
Duffaud, Florence [Auteur]
Feuvret, Loic [Auteur]
Bonneville-Levard, Alice [Auteur]
Bay, Jacques-Olivier [Auteur]
Vauleon, Elodie [Auteur]
Vinceneux, Armelle [Auteur]
Noel, Georges [Auteur]
Penel, Nicolas [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Mir, Olivier [Auteur]

Journal title :

European journal of cancer (Oxford, England . 1990)

Abbreviated title :

Eur. J. Cancer

Volume number :

79

Pages :

119-128

Publication date :

2017-07-01

ISSN :

0959-8049

English keyword(s) :

Chordoma
Molecular targeted therapy
Imatinib
Antiangiogenics
Anti-EGFR
Prognostic factors

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

To assess the role of first-line Molecular Targeted Therapies (MTTs) in Advanced chordoma (AC) patients. Retrospective study of 80 patients treated between January 2004 and December 2015 at 15 major French Sarcoma or ...
Show more >To assess the role of first-line Molecular Targeted Therapies (MTTs) in Advanced chordoma (AC) patients. Retrospective study of 80 patients treated between January 2004 and December 2015 at 15 major French Sarcoma or Neurooncology Centres. The sex ratio M/F was 46/34. The median age was 59 (6-86) years. The primary sites were the sacrum (50, 62.5%), mobile spine (12, 15.0%), and skull base (18, 22.5%). Metastases were present in 28 patients (36.0%). The first line of MTTs consisted of imatinib (62, 77.5%), sorafenib (11, 13.7%), erlotinib (5, 6.3%), sunitinib (1, 1.2%) and temsirolimus (1, 1.2%). The reported responses were: partial response (5, 6.3%), stable disease (58, 72.5%), or progressive disease (10, 12.5%). Symptomatic improvement was seen in 28/66 assessable patients (42.4%) and was associated with an objective response occurrence (p = 0.005), imatinib (p = 0.020) or erlotinib use (p = 0.028). The median progression-free survival (PFS) was 9.4°months (95% CI, [6.8-16.1]). Two independent factors of poor prognosis for PFS were identified: a skull-based primary location (HR = 2.5, p = 0.019), and the interval between diagnosis and MTT of <52months (HR = 2.8, p < 0.001). The median overall survival (OS) was 4.4°years (95% CI, [3.8-5.6]). Four independent factors of poor prognosis for OS were identified: the presence of liver metastases (HR = 13.2, p < 0.001), pain requiring opioids (HR = 2.9, p = 0.012), skull-based primary location (HR = 19.7, p < 0.001), and prior radiotherapy (photon alone) (HR = 2.5, p = 0.024). The PFS and OS did not significantly differ between the MTT. The prognostic factors identified require validation in an independent database but are potently useful to guide treatment decisions and design further clinical trials.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

CHU Lille
Université de Lille

Collections :

• METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694

Submission date :

2019-12-09T18:16:44Z